Skip to main content
Log in

Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Introduction

To investigate the effect of zoledronic acid on periprosthetic bone mineral density (BMD) and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.

Methods

From November 2015 to April 2016, 40 female patients who met the inclusion criteria were randomized into two groups: a control group (calcium + calcitriol) and a zoledronic acid group (calcium + calcitriol + zoledronic acid). At 1 week and 3, 6, and 12 months after operation, BMD was obtained through dual-energy X-ray absorptiometry (DEXA). At pre-operation and at 3, 6, and 12 months after the operation, levels of bone metabolism markers were obtained by serum examination.

Results

Loss of BMD was significantly more pronounced in the control group than in the ZOL group in zones 1, 4, 6, and 7 at 6 months and in zones 1, 2, 4, 6, and 7 at 12 months after the operation. The levels of bone-resorption marker (β-CTX) were significantly lower in the ZOL group than in the control group at 3, 6, and 12 months after operation. The levels of bone-formation marker (TP1NP) performed statistically differences only at 12 months after the operation in these two groups.

Conclusions

Receiving an intravenous infusion of 5 mg zoledronic acid after THA can effectively reduce periprosthetic BMD loss and improve bone remodeling in females with postmenopausal osteoporosis.

Summary

Zoledronic acid significantly inhibited bone mass loss in zones 1, 2, 4, 6, and 7 after THA and inhibited bone-resorption marker (β-CTX) to improve bone remodeling. Zoledronic acid treatment is potentially important for patients with osteoporosis after THA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Enisa Shevroja, Jean-Yves Reginster, … Nicholas C. Harvey

References

  1. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733

    Article  CAS  PubMed  Google Scholar 

  2. Godoy Monzón D, Iserson KV, Jauregui J, Musso C, Piccaluga F, Buttaro M (2014) Total hip arthroplasty for hip fractures: 5-year follow-up of functional outcomes in the oldest independent old and very old patients. Geriatr Orthop Surg Rehabil 5:3–8

    Article  PubMed  Google Scholar 

  3. Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM (2001) Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry – a 3-year follow-up study. J Bone Miner Res 16:1056–1061

    Article  CAS  PubMed  Google Scholar 

  4. Bodén HS, Sköldenberg OG, Salemyr MO, Lundberg HJ, Adolphson PY (2006) Continuous bone loss around a tapered uncemented femoral stem: a long-term evaluation with DEXA. Acta Orthop 77:877–885

    Article  PubMed  Google Scholar 

  5. Furnes O, Lie SA, Espehaug B, Vollset SE, Engesaeter LB, Havelin LI (2001) Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987–99. J Bone Joint Surg (Br) 83:579–586

    Article  CAS  Google Scholar 

  6. Nguyen ND, Eisman JA, Nguyen TV (2006) Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 21:340–349

    Article  CAS  PubMed  Google Scholar 

  7. Knusten AR, Ebramzadeh E, Longjohn DB, Sangiorgio SN (2014) Systematic analysis of bisphosphonate intervention on periprosthetic BMD as a function of stem design. J Arthroplast 29:1292–1297

    Article  Google Scholar 

  8. Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M (2009) Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res 27:183–188

    Article  PubMed  Google Scholar 

  9. Scott DF, Woltz JN, Smith RR (2013) Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial. J Arthroplast 28:671–675

    Article  Google Scholar 

  10. Khatod M, Inacio MC, Dell RM, Bini SA, Paxton EW, Namba RS (2015) Association of bisphosphonate use and risk of revision after THA: outcomes from a US total joint replacement registry. Clin Orthop Relat Res 473:3412–3420

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bell KJ, Hayen A, Glasziou P, Irwig L, Eastell R, Harrison SL, Black DM, Bauer DC (2016) Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data. J Bone Miner Res 31:1767–1773

    Article  CAS  PubMed  Google Scholar 

  12. Aro HT, Alm JJ, Moritz N, Mäkinen TJ, Lankinen P (2012) Low BMD affects initial stability and delays stem osseointegration in cementless total hip arthroplasty in women: a 2-year RSA study of 39 patients. Acta Orthop 83:107–114

    Article  PubMed  PubMed Central  Google Scholar 

  13. Muratore M, Quarta E, Quarta L, Calcagnile F, Grimaldi A, Orgiani MA, Marsilio A, Rollo G (2012) Ibandronate and cementless total hip arthroplasty: densitometric measurement of periprosthetic bone mass and new therapeutic approach to the prevention of aseptic loosening. Clin Cases Miner Bone Metab 9:50–55

    PubMed  PubMed Central  Google Scholar 

  14. Lin T, Yan SG, Cai XZ, Ying ZM (2012) Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int 23:1823–1834

    Article  CAS  PubMed  Google Scholar 

  15. Zhao X, Hu D, Qin J, Mohanan R, Chen L (2015) Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis. J Orthop Surg Res 10:65

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chao M, Hua Q, Yingfeng Z (2013) Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 29:1381–1384

    PubMed  PubMed Central  Google Scholar 

  17. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interaction with hydroxyapatite. Bone 38:617–627

    Article  CAS  Google Scholar 

  18. Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T (2016) Teriparatide versus alendronate for the preservation of bone mineral density after Total hip arthroplasty - a randomized controlled trial. J Arthroplast 31:333–338

    Article  Google Scholar 

  19. Tankó LB, Mouritzen U, Lehmann HJ, Warming L, Moelgaard A, Christgau S, Qvist P, Baumann M, Wieczorek L, Hoyle N, Christiansen C (2003) Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32:687–693

    Article  CAS  PubMed  Google Scholar 

  20. Slovik DM, Adams JS, Neer RM, Holick MF, Potts JT Jr (1981) Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 305:372–374

    Article  CAS  PubMed  Google Scholar 

  21. Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH) D level needed to maintain a favorable bisphosphonate response is ≥33ng/ml. Osteoporos Int 23:2479–2487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bjork A, Mellstrom D, Ohlsson C, Karlsson M, Mallmin H, Johansson G, Ljunggren O, Kindmark A (2018) Haplotypes in the CYP2R1 gene are associated with levels of 25(OH) D and bone mineral density, but not with other markers of bone metabolism. PLoS One 13:12

    Article  Google Scholar 

  23. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362

    Article  CAS  PubMed  Google Scholar 

  24. Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R (2009) The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am 91:274–281

    Article  PubMed  Google Scholar 

  25. Nagae M, Hiraga T, Yoneda T (2007) Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 25:99–104

    Article  PubMed  Google Scholar 

  26. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National High Technology Research and Development Program of China (2015AA020316), Jiangsu Province’s Key Medical center, Jiangsu Provincial Special Program of Medical Science (BL2012004), Natural Science Foundation of Jiangsu Province (BK20180001), the Jiangsu Provincial Medical Youth Talent (QNRC2016751), and the National Nature Science Foundation of China (grant nos. 81873990, 81873991, 81672238, 81572183, 81472077, 81372018).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to H. Yang, Y. Xu or D. Geng.

Ethics declarations

Conflicts of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, W., Liu, Y., Guo, X. et al. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. Osteoporos Int 30, 1581–1589 (2019). https://doi.org/10.1007/s00198-019-05005-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-019-05005-7

Keywords

Navigation